L
Laurent Arnould
Researcher at French Institute of Health and Medical Research
Publications - 218
Citations - 7888
Laurent Arnould is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 41, co-authored 178 publications receiving 6599 citations. Previous affiliations of Laurent Arnould include University of Burgundy.
Papers
More filters
Journal ArticleDOI
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu,Takahiro Yamazaki,Erika Vacchelli,Kariman Chaba,David Enot,Julien Adam,Ilio Vitale,Aicha Goubar,Elisa E. Baracco,Catarina Remédios,Laetitia Fend,Dalil Hannani,Laetitia Aymeric,Yuting Ma,Mireia Niso-Santano,Oliver Kepp,Joachim L. Schultze,Thomas Tüting,Filippo Belardelli,Laura Bracci,Valentina La Sorsa,Giovanna Ziccheddu,Paola Sestili,Francesca Urbani,Mauro Delorenzi,Magali Lacroix-Triki,Virginie Quidville,Rosa Conforti,Jean Philippe Spano,Lajos Pusztai,Vichnou Poirier-Colame,Suzette Delaloge,Frédérique Penault-Llorca,Sylvain Ladoire,Laurent Arnould,Joanna Cyrta,Marie Charlotte Dessoliers,Alexander M.M. Eggermont,Marco Bianchi,Mikael J. Pittet,Camilla Engblom,Christina Pfirschke,Xavier Préville,Gilles Uzé,Robert D. Schreiber,Melvyn T. Chow,Mark J. Smyth,Enrico Proietti,Fabrice Andre,Guido Kroemer,Laurence Zitvogel +50 more
TL;DR: The data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens, and it is surmised that such 'viral mimicry' constitutes a hallmark of successful chemotherapy.
Journal ArticleDOI
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
Laurent Arnould,M. Gelly,Frédérique Penault-Llorca,L. Benoit,Franck Bonnetain,C. Migeon,V. Cabaret,V. Fermeaux,Philippe Bertheau,J. Garnier,Jean-François Jeannin,Bruno Coudert +11 more
TL;DR: An in vivo role for immune (particularly NK cell) responses in the mechanism of trastuzumab action in breast cancer is supported, which may partially account for the synergistic activity of trastsizumab and docetaxel in Breast cancer.
Journal Article
Concurrent and Independent Genetic Alterations in the Stromal and Epithelial Cells of Mammary Carcinoma: Implications for Tumorigenesis
Farid Moinfar,Yan Gao Man,Laurent Arnould,Gary L. Bratthauer,Manfred Ratschek,Fattaneh A. Tavassoli +5 more
TL;DR: The mammary stroma may play a key role in inducing neoplastic transformation of epithelial cells, recapitulating its role in normal mammary duct development, and the concept of stromal-epithelial interaction in the development and progression of mammary neoplasia is supported.
Journal ArticleDOI
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Sylvain Ladoire,Laurent Arnould,Lionel Apetoh,Bruno Coudert,François Martin,Bruno Chauffert,Pierre Fumoleau,François Ghiringhelli +7 more
TL;DR: Findings indicate that pCR to neoadjuvant chemotherapy is associated with an immunologic profile combining the absence of immunosuppressive Foxp3 cells and the presence of a high number of CD8 T cells and cytotoxic cells, arguing for the induction of an antitumor immune response by chemotherapy.
Journal ArticleDOI
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Elisabeth Luporsi,Fabrice Andre,Frédérique Spyratos,Pierre-Marie Martin,Jocelyne Jacquemier,Frédérique Penault-Llorca,Nicole Tubiana-Mathieu,Brigitte Sigal-Zafrani,Laurent Arnould,Anne Gompel,Caroline Egele,Bruno Poulet,Krishna B. Clough,Hubert Crouet,Alain Fourquet,Jean-Pierre Lefranc,Carole Mathelin,Nicolas Rouyer,Daniel Serin,Marc Spielmann,Margaret Haugh,Marie-Pierre Chenard,Etienne Brain,Patricia de Cremoux,Jean-Pierre Bellocq +24 more
TL;DR: KI-67 is an independent prognostic factor for disease-free survival in multivariate analyses studies using samples from randomized clinical trials with secondary central analysis of the biomarker, and its prognostic and predictive value is focused on.